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Inﬂammations are characterized by the release of proteases that overwhelm their
natural inhibitors. Cysteine cathepsins (CPs) that are implicated in bronchial tissue
injuries emerge as key players in pulmonary inﬂammations, including cystic ﬁbrosis.
Among CPs, cathepsin L is an endopeptidase while cathepsin B also acts as a
carboxypeptidase because of the presence of an additional occluding loop. In spite
of kininogens (HMWK), that belong to the cystatin family, tightly inhibit CPs, they
are degraded at inﬂammatory sites. Unexpectedly we found that both cathepsins
B and L process HMWK under stoichiometric conditions. Therefore to understand
such puzzling results, we explored molecular mechanisms of CP inhibition.
While their initial inhibitory potential remained apparently unchanged, structural
rearrangements of HMWK occured following complexation with cathepsins and
both CPs hydrolyzed it at cystatin-like interdomains. Conversely, cathepsin B, but
not cathepsin L, cleaved inside the D3 cystatin domain in the close vicinity of
the inhibitory domain, explaining its weaker inhibition by HMWK. Engineering of
cathepsin B mutants demonstrated that the lack of a functional occluding loop, in
addition to the impairment of the carboxypeptidase activity, restored an efﬁcient
inhibition (Ki values similar to cathepsin L inhibition), consistently with molecular
modeling studies and docking calculations.
According to HMWK may associate with surfactant protein A (SP-A), we will now
analyze consequences on inhibitory potential of HMWK, and on anti-microbial
properties of SP-A, a major player of lung innate immunity.
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Introduction: ABPA is an important complication of pulmonary disease in CF,
occurring in 1−15% of patients. Some centres have reported a signiﬁcant increase:
reports of geographical clustering of cases suggest an increased exposure to
Aspergillus fumigatus (Af). We speculated that this is due to an increase in Af,
in turn due to altered climatic conditions. To look at this further, we compared
immunological markers of Af exposure in our patients with local meteorological
changes over the last 8 years.
Patients and Methods: Of 202 adult CF patients, we selected those 84 (mean age
29 years [range 20 to 52], 45 male) who had Af speciﬁc IgG (AfSI) above the normal
range (40mg/ml), and compared these levels with data from the meteorological
ofﬁce (Station Number 7326; Latitude 53º20′ N, Longitude 3º5′ W; Grid Ref SJ
302755, Elevation 30m), for the years 2001−8.
Results: There was a signiﬁcant increase in AfSI over time (r = 0.622, P< 0.001).
Although there was no change in the average annual temperature (10.6oC), rainfall
increased (mean change +3 cm/year) and there was a strong correlation between this
and also relative humidity and AfSI (r = 0.67 and 0.95 respectively, both p< 0.001).
AfSI levels recorded in the Autumn and Winter months tended to be higher.
Conclusion: The results of global warming in the North West UK have resulted in
a wetter, rather than a warmer climate. In turn, this appears to have produced
conditions which are more suited to the growth of Aspergillus fumigatus, as
witnessed by increased immunological makers to this organism in our CF patients.
It is likely that ABPA will therefore increase in frequency as a result of this
meteorological change.
230 Voriconazole therapy in children with cystic ﬁbrosis and
steroid-dependant allergic bronchopulmonary aspergillosis:
Efﬁcacy and adverse effects
A. Katelari1, J. Limbari1, A. Kapi1, K. Xenofonte1, S. Doudounakis1. 1CF
Center, “Aghia Sophia” Children’s Hospital, Athens, Greece
Introduction: Treatment of ABPA is based on long term corticosteroid use. This
often leads to inability to taper the high doses of corticosteroids (steroid-dependant
ABPA). In such cases, it would be beneﬁcial to use antifungal, such as voriconazole,
to reduce the burden of A. fumigatus (AF).
Study objectives:1) to evaluate the efﬁcacy of voriconazole in patients with cystic
ﬁbrosis (CF) and ABPA, who are difﬁcult to withdraw from prolonged (more than
8 months) courses of steroids (steroid-dependant ABPA) and 2) to monitor the
adverse effects of voriconazole therapy.
Patients and Methods: Seven children (6 boys) aged 11−16 years (median 14years)
with CF and steroid-dependant ABPA were included. Total serum IgE and speciﬁc
IgE on RAST against AF, and use of oral prednisolone, were determined prior and
after a 6-month voriconazole course.
Results: After voriconazole course, total serum IgE fell from a median of 1001
IU/ml (range 3007–275) to 369 IU/ml (range 1379−83). Speciﬁc IgE also fell
from a median of 13.5 IU/ml (25−1) to 6.2 (16−2). During voriconazole course,
a reduction of prednisolone dosages from a median of 30mg every alternate day
(range 45−20) to 12.5mg (range 30−0) was accomplished. Adverse effects attributed
to voriconazole were: a) rash in 6 children (86%), b) elevation of hepatic enzymes
in 4 children (57%), c) visual problems in 2 patients (28.5%) and d) hair loss in
1 patient (14%). No child had any symptoms of adrenal insufﬁciency.
Conclusion: Voriconazole use in patients with CF and steroid-dependant ABPA
may lead to serological improvement and allow tapering of steroid dosage by 60%.
The adverse effects, although frequent, were transient and, in most cases, mild.
